Guardant Health (GH) Tops Q1 EPS by 26c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
April 30, 2025 4:05 PM EDTRevenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data
Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20%
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights
For the three-month period ended March 31, 2025, as compared to the same period of 2024:
Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of... More